Targeting the Tumor Microenvironment in R/M SCCHN

NCT03844763 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Avelumab
DRUG: CTX
RADIATION: RT

Sponsor

Gruppo Oncologico del Nord-Ovest